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ABSTRACT
Foxa2 is a critical transcription factor that controls
liver development and plays an important role in
hepatic gluconeogensis in adult mice. Here, we use
genome-wide location analysis for Foxa2 to identify
its targets in the adult liver. We then show by
computational analyses that Foxa2 containing cis-
regulatory modules are not constructed from a
random assortment of binding sites for other tran-
scription factors expressed in the liver, but rather
that their composition depends on the strength of
the Foxa2 consensus site present. Genes containing
a cis-regulatory module with a medium or weak
Foxa2 consensus site are much more liver-specific
than the genes with a strong consensus site. We not
only provide a better understanding of the mecha-
nisms of Foxa2 regulation but also introduce a novel
method for identification of different cis-regulatory
modules involving a single factor.
INTRODUCTION
Transcriptional regulation in mammals is a complex
and highly orchestrated process. One level of control is
through the binding of transcription factors to speciﬁc
sequences of DNA. Most mammalian transcription fac-
tors do not act alone, but instead work with other factors
to form cis-regulatory modules to control gene expression
(1). Over the last several years, cis-regulatory systems in
the liver have been studied in detail (2–12). Some of these
studies focused on individual binding and potential inter-
actions between known hepatic regulators, but did not
attempt to exploit computational tools to identify addi-
tional transcription factors that may be a part of the reg-
ulatory modules operative in the liver (2,6–8). Another
group of studies utilized tissue-speciﬁc gene-expression
information, and then identiﬁed cis-regulatory modules
in promoter regions of tissue-speciﬁc genes, but did not
take into account any in vivo binding data (9–12).
One factor that is known to play an important role in
regulating gene expression in the liver is Foxa2. Foxa2 is a
member of the Foxa subfamily of Forkhead transcription
factors, characterized by a highly conserved 110 amino
acid motif that functions as a DNA-binding domain (13).
Gene ablation studies have demonstrated that Foxa2 is a
critical factor in the development of the liver, and is also
an important regulator of the gluconeogenic program in
adult mice (14,15). Genome-wide location analysis has
been carried out to identify potential Foxa2 targets in
HepG2 hepatoma cells and primary hepatocytes (2,7).
These studies conﬁrmed that Foxa2 is commonly bound
to promoter regions in which other hepatic transcription
factors are also bound, which had also been described in
previous studies of promoters and enhancers of individual
genes. For example, Foxa2 binds to the Fabpl promoter
region, where hepatocyte nuclear factor (HNF) HNF-1,
C/EBP-b, GATA-4 and HNF4-a also bind, and also acti-
vates transthyretin (TTR) expression by cooperating with
other factors in its promoter and enhancer (16,17).
The aim of this study was to identify additional factors
that potentially interact with Foxa2. Using genome-wide
location analysis combined with computational methods,
we identify several potential binding partners of Foxa2
and show that the likelihood of a given factor’s consensus
sequence to be found near Foxa2 is dependent on the
strength of the Foxa2-binding site.
MATERIALS AND METHODS
Chromatin immunoprecipitation (ChIP)
ChIPs were performed as described previously (5).
Mouse livers were minced ﬁnely in cold phosphate-
buﬀered saline (PBS) and cross-linked in 1% formaldehyde
for 10min while rotating. Cross-linking was quenched by
adding glycine to a ﬁnal concentration of 0.125M for 5min
while rotating. The tissue was rinsed in cold PBS and
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buﬀer (10mM Tris–Cl, pH 8.0, 10mM NaCl, 3mM
MgCl2, 0.5% NP-40) and protease inhibitors. Cells were
incubated at 48C for 5min to release nuclei. Nuclei were
centrifuged at 13000g for 5min to form a pellet. The pellet
wasresuspendedinnuclearlysisbuﬀer[1%sodiumdodecyl
sulfate (SDS), 5mM EDTA, 50mM Tris–Cl, pH 8.1) and
protease inhibitors and sonicated using the Diagenode
Bioruptor for 10min on high, using 30s intervals. Debris
were removed by centrifugation at 13000g for 10min, and
the supernatant was collected and snap frozen in liquid
nitrogen. A 10ml aliquot was reversed by the addition of
NaCl to a ﬁnal concentration of 192mM, overnight incu-
bation at 658C, and puriﬁcation using a PCR puriﬁcation
kit (Qiagen, CA, USA). The chromatin concentration was
determined using a NanoDrop 3.1.0 nucleic acid assay
(Agilent Technologies, Santa Clara, CA, USA).
Ten micrograms of chromatin per sample was pre-
cleared by adding 90ml of protein G-agarose in 1ml of
ChIP dilution buﬀer (0.01% SDS, 1.1% Triton X-100,
167mM NaCl, 16.7mM Tris–Cl, pH 8.1) and rotating
the sample for 1h at 48C. Protein G-agarose was sedimen-
ted by centrifugation at 3000g for 30s. Two micrograms
of rabbit anti-Foxa2 serum (provided by J.A. Whitsett),
was added to the supernatant and incubated overnight at
48C. Protein G-agarose was blocked overnight at 48C with
1mg/ml bovine serum albumin and 0.1mg/ml herring
sperm DNA in ChIP dilution buﬀer, added to the chro-
matin, and rotated for 1h at 48C. Following three conse-
cutive washes of 5min each with TSE I (0.1% SDS, 1%
Triton X-100, 2mM EDTA, 20mM Tris–Cl, pH 8.1,
150mM NaCl), TSE II (0.1% SDS, 1% Triton X-100,
2mM EDTA, 20mM Tris–Cl, pH 8.1, 500mM NaCl)
and ChIP buﬀer III (0.25M LiCl, 1% NP-40, 1% deoxy-
cholate, 1mM EDTA, 10mM Tris–Cl, pH 8.1), chromatin
was eluted by adding 100ml of freshly made ChIP elution
buﬀer (1% SDS, 0.1M NHCO3) to the pellet and rotating
the sample for 10min. Elution was repeated with an addi-
tional 100ml of ChIP elution buﬀer, and the eluates were
combined. Cross-linking was reversed by the addition of
NaCl to a ﬁnal concentration of 192mM and overnight
incubation at 658C.
Ligation-mediated PCR (LM-PCR)
DNA blunting, linker ligation and ampliﬁcation were car-
ried out following the Agilent Mammalian ChIP-on-chip
Protocol (http://www.chem.agilent.com/scripts/Literature
PDF.asp?iWHID=42637).
LabelingandhybridizationtomousepromoterchipBCBC-5A
LM-PCR ampliﬁed ChIP DNA was labeled using the
BioPrime Array CGH Genomic Labeling System
(Invitrogen Life Technologies, CA, USA) as per manufac-
turer’s instructions. Brieﬂy, 1mg of DNA was mixed with
random primers and denatured at 958C for 5min, then
cooled brieﬂy on ice. Next, the appropriate Cyanine
dUTP ﬂuorescent nucleotides (PerkinElmer Life And
Analytical Sciences, Inc., MA, USA) were added, along
with the nucleotide mix and Exo Klenow fragment. This
was gently mixed and incubated at 378C for 2h. The Cy3
and Cy5 labeled samples were puriﬁed using the MinElute
PCR Puriﬁcation Kit (Qiagen), and the eﬃciency of
dye incorporation and yield was determined using the
NanoDrop ND-1000 UV-Vis Spectrophotometer. The
Cy5 and Cy3 labeled samples were combined and 1mg
of Mouse Cot1 DNA (Invitrogen Life Technologies) was
added to each sample and denatured at 958C for 5min.
The samples were then cooled to 428C and an equal
volume of 2hybridization buﬀer (50% formamide,
10SSC and 0.2% SDS) was added, mixed and applied
to the array.
The BCBC-5A chip contains over 18000 proximal and
distal promoterregions. Promoterregions were determined
from full-length cDNA libraries and Reference Sequences
(RefSeqs). Over 12000 well-characterized genes were
chosen and are represented by either a 1- or 2-kb tile,
PCR ampliﬁed from genomic material. Microarray slides
were hybridized overnight, then washed and scanned with
Agilent G2565BA Microarray Scanner. Images were ana-
lyzed with GenePix 5.0 software (Axon Instruments,
Molecular Devices, Union City, CA, USA).
Data processing and analysis
Median foreground intensities were obtained for each spot
and imported into the mathematical software package ‘R’
(http://www.r-project.org/), which is used for all data
input, diagnostic plots, normalization and quality check-
ing steps of the analysis process using scripts developed in-
house. The ratio of expression for each element on the
array was calculated in terms of M[log2(Red/Green)]
and A[(log2(Red)+log2(Green))/2)]. The dataset was
ﬁltered to remove positive control elements (Cy3 anchors
and SpotReport elements) and any elements that had been
manually ﬂagged as poor quality. The M-values were
then normalized by the print tip loess method using the
‘marray’ microarray processing package in ‘R’. Statistical
analysis was performed in ‘R’ using both the LIMMA and
SAM packages. Foxa2 targets were deﬁned as elements
that had an expression ratio greater than 1.3 and a false
discovery rate (calculated by SAM) of less than 10%.
Identification ofenriched binding sites
Position weight matrices (PWMs) from the TRANSFAC
database were scanned across target (bound) sequences,
and 1000 random sequences from the Promoter Chip
BCBC 5A (unbound) sequences, which were used as back-
ground. All Promoter Chip tile sequences were padded by
300bp on each end. Only the top scoring match to the
PWM for each sequence was analyzed further. For several
score cutoﬀs, the number of true positives (target seque-
nces with a score above the cutoﬀ), and the number of
false positives (background sequences with a score above
the cutoﬀ) were calculated. Plotting the true positive frac-
tion versus the false positive fraction produces a receiver
operating characteristic curve (ROC curve). ROC curves
were generated for all PWMs, and then the area under the
curve (AUC) was calculated. The 100 permutations were
carried out by combining target sequences and back-
ground sequences into one set, and then randomly select-
ing 107 sequences from the set. This set was treated as
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background. The P-value was then calculated by counting
the number of times the AUC in the random target sets
exceeded the real AUC, divided by 100. A PWM was
considered to be enriched if the AUC was >0.5, and the
P-value was 0.01.
Quantitative RT–PCR
Real-time PCRs were assembled using SYBR GreenER
(Invitrogen). Reactions were performed in triplicate
using the Mx3000 PCR System (Stratagene, La Jolla,
CA, USA). The enrichment of target genes was calculated
using the 28S rRNA locus as a reference for nonspeciﬁc
DNA, and was calculated by comparing input (sheared
genomic DNA) to ChIP material. Primer sequences are
provided in Supplementary Table 7.
RESULTS
Genome-wide location analysis
We carried out ChIP with ﬁve biological replicates of
adult mouse liver using a speciﬁc Foxa2 antibody as
described previously (18). We validated the speciﬁcity
of this antibody by conﬁrming that the Foxa2 promoter,
which Foxa2 itself is normally bound to, is no longer
occupied when ChIP is carried out using the livers
of Foxa2
loxP/loxP Alfp.Cre mice, which lack Foxa2 in
hepatocytes (2,19,20) (Figure 1A and B). ChIP samples
from the wild-type mice were ampliﬁed, labeled and
hybridized to the Mouse Promoter Chip 5A, which con-
tains over 18000 promoter and enhancer elements. Using
the computational tools and statistical methods described
in ‘Materials and methods’ section, we identiﬁed 107
Foxa2 target sites in the liver (Figure 1C, Supplementary
Table 1). We used the hypergeometric distribution to show
that this set of targets overlaps signiﬁcantly with the genes
identiﬁed in a prior location analysis of human primary
hepatocytes (2) (Supplementary Table 2).
Scanning ofPWMs
ToidentifypotentialinteractingpartnersofFoxa2,weused
the transcription factor binding site (TFBS) module in
Bioperl (21) in order to identify overrepresented cis-regu-
latory elements. After scanning all of the vertebrate PWMs
contained in the TRANSFAC database on both Foxa2
target sequences and unbound background sequences,
Figure 1. Validation of Foxa2 antibody and results of genome-wide location analysis. (A and B) Chromatin from livers of wild-type and
Foxa2
loxP/loxP Alfp.Cre mice was immunoprecipitated with an anti-Foxa2 antibody. Input chromatin and precipitated DNA were ampliﬁed with
primers surrounding the Foxa2-binding site in the Foxa2 promoter. Occupancy of the Foxa2 site is not detected in Foxa2
loxP/loxP Alfp.Cre mice both
in a qualitative assay (A) and using quantitative real-time PCR (B). In (B), enrichment was calculated relative to the input chromatin and by using
the 28S rRNA locus as a control. (C) Chromatin was isolated from the liver of ﬁve adult mice. Chromatin was cross-linked, sheared and
immunoprecipitated with the Foxa2-speciﬁc antibody described in A and B. The resulting material was uncross-linked, ampliﬁed and labeled.
Material that was not immunoprecipitated was also ampliﬁed and labeled with a diﬀerent dye. Both sets were hybridized on the Mouse
Promoter Chip BCBC 5A. Statistical analysis resulted in a set of 107 genes that are bound by Foxa2.
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ing sites for each DNA-binding protein. The AUC calcu-
lated from the ROC curve of Foxa2 (Figure 2A) was >0.5,
conﬁrming that the PWM for Foxa2 is a reasonable
approximation of the preferred in vivo contact site.
Because 300 of the 524 PWMs scanned had an AUC
>0.5, we performed 100 permutations of the data to
obtain a reference distribution, which we employed to cal-
culate an approximate P-value for each ROC curve.
Interestingly, the ROC curve shows that the likelihood of
ﬁnding the Foxa2 consensus sequence (PWM) in the target
sequences is only slightly above that of ﬁnding it in the
background sequences, no matter what cutoﬀ score for
the PWM is chosen. The score distribution for Foxa2 in
target sequences and background sequences shows that the
consensus sequence is frequently found throughout the
genome (Figure 2B). In other words, the Foxa2 consensus
sequence does not contain suﬃcient information to predict
real in vivo occupancy among the background of thousands
of unbound promoters with similar sequences, similar to
what has been observed previously for other transcription
factors (22,23). This ﬁnding suggests that Foxa2 in vivo
binding might be determined by additional sequences
elements.
Foxa2 consensus strength and enrichmentof other
transcription factor bindingsites
Enhancers are often composed of binding sites for multi-
ple transcription factors. In the liver, these might include
sites for the HNFs, nuclear hormone receptors and others
(2,3,9,10). Thus, ‘liver-modules’ can be made up of
binding sites for HNF6, HNF4-a, HNF-1a, Foxa2 etc.
In principle, a given enhancer strength of a liver-module
could be achieved by combinations of various strong and
weak binding sites for multiple factors. We have shown
that Foxa2 can bind to sequences that either strongly
match the existing consensus or are a weak match.
Therefore, we investigated whether the role of additional
factors between these strong and weak cases is diﬀerent.
To this end, we compared the enrichment of cis-regulatory
elements in sequences that have a weak match to the
Foxa2 consensus to those sequences that have a strong
match by ﬁrst ordering the Foxa2 target sequences by
decreasing Foxa2 PWM score. Starting with the ﬁrst 10
sequences, which have the highest Foxa2 PWM score, we
calculated the AUC for other transcription factor PWMs
of interest, focusing on those PWMs that had an AUC
>0.5, and a P-value 0.01 when all target sequences
were scanned (Supplementary Table 3). We then itera-
tively added in the remaining Foxa2 target sequences,
one by one, while recalculating the AUC after each addi-
tion (Figure 3A). As shown in Figure 3B, the AUC of
Foxa2 steadily decreases as sequences with weaker binding
sites are added, as expected. Plotting the AUC for other
transcription factors against the number of sequences
gives us the ‘AUC path’. The AUC paths for each of the
other transcription factors indicates which TF-binding
sites are either enriched more or less as the strength of
the Foxa2-binding site decreases. If a particular factor is
not dependent on the match to the Foxa2 PWM, its AUC
path should remain constant as Foxa2 target sequences
are added (Figure 3B). In order to identify factors that
show a dependence to the match to the Foxa2 PWM,
we calculated the area between the AUC path of each
other factor and the AUC path for Foxa2 itself
(Figure 3C). The binding sites that are more enriched in
the presence of a close match to the Foxa2 consensus have
the smallest area between the AUC paths, whereas the
factors that are less enriched in the presence of a strong
Foxa2 site have the largest area between AUC paths.
Strikingly, several of the PWMs analyzed show a relation-
ship between their own enrichment and the PWM score
for Foxa2, suggesting that in the liver, Foxa2 containing
cis-regulatory modules are not assembled at random
(Supplementary Table 4). The binding sites for two fac-
tors, HNF-1a (Transfac ID: M00132, HNF1_01), which
has an important role in hepatic and intestinal gene reg-
ulation, and Jun (Transfac ID: M00036, VJUN_01),
which is involved in hepatocyte proliferation, showed
the strongest dependence on the Foxa2 PWM score
(Figure 3C) (24,25). The enrichment of the HNF-1a
Figure 2. Scanning of Foxa2 PWM from TRANSFAC. (A) ROC curve
generated from scanning Foxa2 PWM on target (bound in genome-wide
location analysis) and background sequences. When scanning PWMs,
only the highest scoring match is used for further analysis. The PWM is
only slightly enriched in sequences that are bound by Foxa2 (black line).
ROC curve generated from scanning a random set of background
sequences (dark gray line) is similar to the theoretical line for ROC-
based analysis (light gray line). (B) Distribution of scores for Foxa2
PWM found in target and background sequences. The Foxa2 consensus
is easily found in random sequences, and the match to the consensus
sequence does not have to be strong for the factor to bind DNA.
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the enrichment of the Jun PWM increases (Figure 4A and
B). To evaluate the signiﬁcance of this dependence, we
permuted the sequence order 100 times, so that it was
no longer indicative of the match to the Foxa2 consensus,
and repeated the method for calculating the AUC path of
the other TFs and the area between AUC paths described
earlier. Calculating the area between AUC paths for
Foxa2 and all of the permutations for HNF-1a and Jun
shows that the observed value obtained when using the
actual ordering of sequences by Foxa2 binding site
strength is not random (Figure 4C and D). To further
validate the dependence of HNF-1a and Jun PWM enrich-
ment on Foxa2 PWM score, we selected background
(unbound) sequences that contain the same distribution
of Foxa2 PWM scores as the target sequences. As
expected, the AUC path for HNF-1a and Jun remains
constant as sequences are added, conﬁrming that the
dependence of PWM enrichment we see in our target set
is not simply the result of sequence composition bias
(Figure 4E and F). We also permuted the background
sequence order to show that unlike what is seen in the
target sequences, when background sequences are ordered
by decreasing Foxa2 score the AUC path does not lie on
the edges of the permuted AUC paths (Figure 4E and F).
While the AUC for Jun calculated using background
sequences has an overall similar AUC to that calculated
using target sequences, the AUC path is not steadily
increasing in the background sequences as it is in the
true target sequences (Figure 4F). However, we note
that the relationship between the Foxa2 PWM score and
the Jun PWM enrichment among the Foxa2 targets deter-
mined from genome-wide location analysis is not as strong
as the relationship seen with HNF-1a. Interestingly, the
de-enrichment of some factors is most dependent on
Foxa2 sequences of medium strength (Figure 4G). One
such factor is PPAR-g (Transfac ID: M00512,
PPARG_01), which is involved in lipid metabolism and
diﬀerentiation of adipocytes (26,27). As shown in
Figure 4H, when sequences that have the strongest
Foxa2 binding sites are removed from analysis, the
PPAR-g enrichment follows a pattern similar to Jun.
Identifying additional TFBS’s relatedto Foxa2 consensus
strength
In the previous section, we only investigated the relation-
ship of PWM scores for Foxa2 and the 70 factors that had
an AUC of >0.5, and a P-value 0.01 when using all 107
Foxa2targets.Itispossiblethatadditionalbindingsitesare
dependent on the match to the Foxa2 consensus, but did
not have a high AUC when all Foxa2 sites were considered
previously. To identify these other factors, we split the
Foxa2 target sequences into two groups—those that have
astrongFoxa2consensus,andthosethathaveamediumto
weak Foxa2 consensus. We explored four possible splits of
the data, where the group that was considered to have
strong match to the Foxa2 consensus consisted of the top
30, 40, 50 or 60 sequences, and the group with medium/
weak binding sites consisted of the remaining sequences for
each split. Because we have already demonstrated that
HNF-1a is strongly associated with strong Foxa2 binding
sites, we chose the grouping of sequences that gave the
most dramatic diﬀerence in the AUC for HNF-1a, which
gave us a grouping of the ﬁrst 40 sequences as the strong
Foxa2-binding sites, and the remaining 67 sequences as the
medium/weak Foxa2 binding sites (Supplementary
Table 5). These groups of sequences contained a similar
overall CG bias and percentage of CpG islands, which
was determined using a CpG island searcher, CpGIE
(28). Of the sequences with a medium/weak match to the
Foxa2 consensus, the average CG bias was 0.021% and
28% of the sequences contained one CpG island. Of the
sequences with a strong match to the Foxa2 consensus, the
average CG bias was 0.022% and 22.5% contained one
CpG island. The diﬀerence in CpG island content in the
two groups was not signiﬁcant, as determined using the test
of equal proportions. We then scanned all of the vertebrate
PWMs in TRANSFAC on both of these sets, again using
‘unbound’ sequences as background, and found that a dif-
ferent group of transcription factors were enriched in
each set. Foxa2 targets closely matching the Foxa2 PWM
preferentially contained binding sites for factors such
as HNF-1a, HNF6 and CEBP, while the targets match-
ing the Foxa2 consensus only weakly were associated
Figure 3. PWMs of other transcription factors are dependent on
Foxa2-consensus score. (A) Method for calculating AUC path, to iden-
tify factors dependent on the Foxa2-consensus score. Sequences were
ordered by decreasing Foxa2 score, and after adding one sequence at a
time, the AUC for all TRANSFAC PWMs with AUC >0.5 and
P-value 0.01 in the 107 Foxa2-target sequences was calculated. (B)
Plotting the AUC against number sequences used in the calculation
gives the AUC path for a factor. The AUC decreases for Foxa2 as
more sequences are added (black line). The AUC for VMYB_01 shows
no dependence on the Foxa2-binding site score (red line). (C) The area
between the AUC path for every factor used in (A) and the AUC path
for Foxa2 is plotted. HNF1_01 and VJUN_01 show the smallest and
largest area between curves.
Nucleic Acids Research, 2008, Vol. 36, No. 12 4153with PPAR-g, HNF4-a CREB, Jun and also USF,
which regulates genes involved in glucose and lipid meta-
bolism (Supplementary Table 6) (29).
Confirmation of medium/weakFoxa2 targets
Since the match to the Foxa2 consensus sequence in our
medium/weak group was relatively poor, we wanted to
ensure that these sites were not false positives from our
genome-wide location analysis. Therefore, we designed
primers around the computationally predicted binding
sites for ﬁve of these target genes, including Serpinf2,
which has the weakest scoring Foxa2 site, and showed
by quantitative RT–PCR that these targets were indeed
enriched in Foxa2 ChIP samples (Figure 5A).
Additionally, we show that neither the predicted binding
site score nor the GOMER score, which was calculated
using the model that takes potential homotypic interac-
tions into account (30), are related to the fold-change
determined from genome-wide location analysis, indicat-
ing that the fold-change cutoﬀ chosen does not have any
impact on the binding site strength (Figure 5B and C).
Figure 4. PWMs that show a dependence on Foxa2-binding site score. (A and B) AUC path for HNF1_01 (A, red) shows that as sequences with
decreasing Foxa2 score are added, enrichment for the factor decreases. AUC path for VJUN_01 (B, red) shows that as sequences with decreasing
Foxa2 score are added, enrichment for the factor increases. Permuted sequences (not depended on Foxa2 score) are in gray. (C and D) Distribution
of area between paths for permuted sequences when scanning for HNF1_01 (C), VJUN_01(D) and Foxa2. Area between curves for the factors
and Foxa2 when sequences are ordered by Foxa2 consensus site strength is in red. (E and F) The 107 background sequences, which contain Foxa2-
binding sites that match the score distribution of binding sites in the Foxa2 targets, were ordered by decreasing Foxa2 PWM score. Permuted
sequence order for the background sequences are in gray. AUC paths for HNF1_01 (E) and VJUN_01 (F) were calculated using these sequences
(blue line), and no longer show a dependence on Foxa2 PWM score, as they did when the true target sequences are used (red). (G) AUC path for
PPARG_01 (red) shows this factor is most enriched in the sequences with very strong or very weak Foxa2-binding sites. Permuted sequences (not
depended on Foxa2 score) are in gray. (H) AUC path for PPARG_01 (red) when the sequences with strongest Foxa2 sites are removed from
analysis. Now the factor shows a trend similar to VJUN_01. As expected, the overall enrichment of Foxa2 is lower when the strongest sequences are
not included in analysis. Permuted sequences (not depended on Foxa2 score) are in gray.
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medium/weak match tothe Foxa2 consensus
Because there are diﬀerent sets of TFBS enriched in
sequences with strong Foxa2 PWM match versus those
with medium/weak Foxa2 PWM scores, we investigated
potential diﬀerences in expression patterns between the
genes in the two groups. To study gene-expression
patterns, we used the Novartis mouse dataset, which pro-
ﬁles gene expression across 91 tissues (31). First, we iden-
tiﬁed which tissue had the highest expression for each
target gene in both the strong and medium/weak Foxa2
consensus groups. In the group with a medium/weak
Foxa2 consensus, 34% of the genes are most abundantly
expressed in the liver, whereas in the group with a strong
Foxa2 consensus, only 14% of the genes are activated
most strongly in the liver (Figure 6A and B).
We next investigated the tissue speciﬁcity of those genes
that are highly expressed in the liver, by ﬁrst calculating
the median expression of each gene across all tissues. We
focused on genes that had high expression in the liver,
with an expression value more than three times the
median. Almost half of the genes in both groups (37%
of the genes that have a strong Foxa2 consensus and
45% of the genes that have a medium/weak Foxa2 con-
sensus) were determined to have high expression in the
liver. Of these genes, we determined the number of other
tissues that also have expression greater than three times
the median expression (Figure 6C and D). It is clear from
Figure 6C and D that the genes which have high expres-
sion in the liver and a medium/weak Foxa2 site are more
tissue speciﬁc, while the genes that have high expression in
the liver and a strong Foxa2 site have high expression in
several other tissues.
DISCUSSION
We have used a novel methodology to demonstrate the
dependence between the strength of a mammalian tran-
scription factor-binding site as determined by its PWM
score and the enrichment of other binding sites in the
same promoter or enhancer region. We used Foxa2
target regions, as determined by genome-wide location
analysis, to show that Foxa2 has the ability to bind
DNA even when the sequence to which it is binding is
not a strong match to the known consensus. To ensure
that the sequences containing weak binding sites were true
targets of Foxa2, we conﬁrmed several with quantitative
RT–PCR. Additionally, we have shown that when there is
a strong match to the Foxa2 consensus, a diﬀerent set of
binding sites for other transcription factors is enriched
when compared to those genes that have a medium or
weak Foxa2 consensus in the promoter region. The idea
that Foxa2 has the ability to bind variations of the con-
sensus sequence with diﬀerent aﬃnities has been shown
previously, using gel shift assays, however, these in vitro
studies could not explain why Foxa2 does not bind to all
‘weak’ sites in the genome (32).
The structure of Foxa2 resembles that of histone H5, as
shown by X-ray crystallography (33). Foxa2 has been
shown to act as a ‘pioneer’ factor in the case of the albu-
min enhancer, where Foxa proteins have the ability to
bind compacted chromatin and make it more accessible
for other transcription factors to bind (34–36). The albu-
min enhancer contains a site with a strong match to the
Foxa2 consensus site, and therefore the question remains
whether Foxa2 has the ability to bind compacted chro-
matin everywhere, or only when strong binding sites
Figure 5. Conﬁrmation of medium/weak Foxa2-target sites. (A)
Conﬁrmation of medium/weak Foxa2 targets by quantitative RT–
PCR. Included in this list is Serpinf2, which had the lowest scoring
Foxa2-binding site. (B) This plot shows that there is no relationship
between fold-change, as determined from the genome-wide location
analysis, and binding site score, as determined by scanning the Foxa2
PWM. (C) GOMER software was used to calculate a score using the
cooperative interaction model to account for homotypic interactions.
For a variety of distance parameters, there was no relationship between
fold-change, as determined from the genome-wide location analysis and
GOMER score (data not shown). Shown here are the GOMER scores
using a maximum distance of 50 and minimum distance of 10 for
homotypic interactions.
Nucleic Acids Research, 2008, Vol. 36, No. 12 4155are present. The discovery of a diﬀerence in binding site
enrichment depending on the strength of the Foxa2 bind-
ing sites could indicate that Foxa2 is acting as a pioneer
factor only when a strong site is present, but has a diﬀer-
ent mechanism for binding target genes when a weak site
is encountered.
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